NewsEvents

Your Yourlocation: Home > Industry News: tiotropium bromide(136310-93-5) production enterprises

Boehringer Ingelheim's COPD compounded its primary goal in a later phase of the trial, clearing the way for its marketing approval, a competition with GlaxoSmithKline.

The inhaled drug is made up of Olodaterol (approved in July under the trade name Striverdi) and tiotropium bromide(136310-93-5) (Spiriva). Among the more than 5500 COPD patients in two of the 52-week phase 3 trials, the combination of the two drugs improved lung function better than the monotherapy of each drug, and each The incidence of adverse events was similar in the treatment groups.

Olodaterol is a long-acting beta2 receptor antagonist (LABA), while tiotropium is a long-acting muscarinic antagonist (LAMA) that is designed to relieve respiratory muscle and relieve COPD symptoms. The drug is part of a new wave of COPD drugs, which analysts predict will ultimately dominate the market.

Currently, Boehringer Ingelheim is waiting for the FDA's final decision, the FDA last month to accept its fixed-dose compound drug listing applications. The company did not disclose when it expected to win approval of the drug, but the agency set a 10-month review deadline for the drug.

At the same time, GlaxoSmithKline has been on sale Anoro Ellipta, this drug by the patent LABA and LAMA treatment drugs. AstraZeneca is not far behind with its compound, which acquired the treatment company of Pearl for $ 1.5 billion and Almirall's respiratory business for $ 2.1 billion to get the COPD compound in a Phase III study. Novartis's fixed-dose LABA / LAMA combination, called Ultibro Breezhaler, was approved in Europe last year.

While behind in the COPD compound drug competition, Boehringer Ingelheim believes that its competitive products can have outstanding performance in this area, will occupy a considerable market share, the size of the market is expected from 2013 to 10 billion US dollars Growing to $ 14 billion in 2018.

Although GlaxoSmithKline is a pioneer, the company has so far struggled to meet Analysts' expectations for Anoro and the recently launched Breo Ellipta, which the company hopes will eventually make up $ 8 billion a year for Seretide US dollars of sales.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved